Conjugation of Monoclonal Antibodies to Super Paramagnetic Iron Oxide Nanoparticles for Detection of her2/neu Antigen on Breast Cancer Cell Lines

Fereshteh Shamsipour 1, Amir Hassan Zarnani 2, Roya Ghods 1, Mahmood Chamankhah 3, Flora Forouzesh 3, Sedigheh Vafaei 1, Ali Ahmad Bayat 1, Mohammad Mehdi Akhondi 2, Mohammad Ali Oghabian 4, and Mahmood Jeddi-Tehrani 1*

1. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
2. Department of Immunology, Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
3. Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
4. Research Centre for Science and Technology in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract
Conjugation of monoclonal antibodies to super paramagnetic nanoparticles is an effective method for cancer diagnosis and treatment. In this study the humanized anti her2/neu monoclonal antibody- Herceptin- was conjugated to super paramagnetic iron oxide (SPIO) nanoparticles using EDC method. The concentration of the conjugated antibodies was measured by Bradford assay. The antibody-nanoparticle conjugates were incubated with SKBR-3 and T47D human breast carcinoma cell lines and the presence of the conjugates on cell surface was confirmed by Prussian blue iron staining method. Conjugation of Herceptin to SPIO resulted in a precipitate-free conjugate containing 20\(\mu\)g antibody/mg SPIO. Prussian blue iron-staining of cells showed successful binding of the conjugates to the cell surfaces. Conjugation of monoclonal antibodies to SPIO may be a useful method for detection of tumor cells, especially by MRI techniques.

Keywords: Breast cancer, Conjugation, Herceptin, Nanomagnetic particles

Introduction
Molecular probes for biomolecular recognition are of great importance in the fields of chemistry, biology, medical sciences and in biotechnology as well. These probes have been used in studies of biological functions and in ultrasensitive detection of biological factors responsible for many diseases (1). On the other front, the developments of nontoxic and biocompatible magnetic particles have been disclosed for biological applications since mid-1980s (2).

Recently, magnetic particles have attracted growing interest as high performance biomaterial which is used for transport and separation of cells or cell parts (2, 3), MRI (4), hyperthermia (5) and drug delivery (6). Biological samples such as blood, serum, cell suspensions and cell lysates are allowed to be exposed to specific ligand-coupled particles, and the captured molecules or cells are then rapidly separated using magnetic fields (3,7,8).
Magnetic particles conjugated with anti tumor monoclonal antibodies provide a new approach to identify tumor cells.

Antibodies labeled with magnetic nanoparticles give magnetic signals on exposure to a magnetic field. Iron oxide particles are usually coated with different organic shells including dextran, albumin or polyethylene glycol. Coated nanoparticles can be manufactured with a variety of functional groups (such as amino, aldehyde, hydroxyl, sulfate and carboxyl groups) on their surfaces. Considering these properties, we used super paramagnetic iron oxide (nanomag-D-SPIO 20 nm) with COOH group on the surface, for conjugation to a humanized anti her2/neu monoclonal antibody (Herceptin) as a cancer targeting antibody.

**Materials and Methods**

Nanomag-D-SPIO 20 nm nanoparticles (surface COOH) and MACS separator with MS columns were purchased from Micromod (Miltényi Biotech GmbH, Germany). The breast carcinoma cell lines SKBR-3 and T47D were obtained from Pasteur Institute of Iran. Other reagents and chemicals were obtained from Merck and Sigma.

Conjugation of anti her2 antibody (Herceptin) with nanoparticles by EDC method

N-ethyl-N-(3-dimethyl aminopropyl) carbodiimide hydrochloride (EDC, 20mM) and 10 mM N-hydroxy succinimide (NHS) were dissolved in 0.1 M 2-(N-morpholino) ethane-sulfonic acid (MES) buffer (pH=8.3). The mixture was added to 1 ml of 5 mg/ml nanomag-D-SPIO 20 nm nanoparticles, and shaken at room temperature for 2 hours.

The particles were washed twice with phosphate buffered saline (PBS) pH=7.4 and then 0.5-1 mg/ml of Herceptin was added to the activated particles. The mixture was shaken for 3 hours and the reaction was quenched by the addition of glycine for 30 minutes. The unconjugated antibodies were separated from conjugated antibodies by MACS column. The amount of immobilized antibody was estimated based on the Bradford method.

*Spectrophotometric measurement of Iron*

Iron concentration of conjugated samples was obtained by potassium thiocyanate method. In brief, samples were diluted with 300 μl 6N HCl containing 1% H2O2; under this condition, the iron in the samples is dissolved and oxidized to ferric state. The samples were then added to a 5% solution of potassium thiocyanate where the Fe III formed a red complex with the thiocyanate which could be measured by absorbance at 480 nm.

**Cell culture**

The her2/neu expressing cell lines SKBR3 and T47D were grown in RPMI 1640 medium with 10% (v/v) fetal calf serum and %1 penicillin/streptomycin. Cells were incubated at 37°C containing 5% Co2.
Immunofluorescence staining

To verify the expression of her2 proteins on the cells, the SKBR3 and T47D cells were incubated with anti her2/neu (Herceptin) at 10 μg/ml concentration for 1 hour at 37°C. After being washed in PBS, FITC-labeled anti human IgG (diluted 1/20, Avicenna Research Institute, Tehran, Iran) was added and incubated for 1 hour at room temperature. Cells were then observed directly on a fluorescence microscope (Olympus, Japan).

In vitro cell labeling

SKBR3 and T47D cells were counted and adjusted to a suspension of 4×10⁵ cells/ml; 100 μl of each cell suspension were cyto-spined on microscope slides (Shandon cyto-spin 4, Thermo, Germany). The cells were incubated with 100 μl magnetic nanoparticles (with or without antibody; 5 μg Ab and 0.2 mg iron) for 1 hour at 37°C. Then cells were washed extensively with PBS to remove unbound particles.

The nanoparticles that bounded on the cell surface were detected by iron staining with Prussian blue staining method (14, 15).

Results

We used 20nm nanoparticles (a magnetic core covered with dextran) with carboxyl group for conjugation to Herceptin as a cancer targeting antibody. The final products of conjugation were suspensions without precipitate and the amount of immobilized antibody was 20-36 μg Ab/mg nanoparticles (Figure 1).

The amount of iron conjugated was determined by potassium thiocyanate method using FeCl₃-6H₂O as a reference (Figure 2).

The SKBR3 and T47D cell lines showed high levels of her2/neu expression, after incubation with Herceptin-FITC (Figure 3), but not with the isotype control antibody (data not shown).

These results confirmed the presence of antigen on the cell surface. Specific binding of the conjugates to the cells can be determined by using electron microscopy, MRI imaging and iron staining (13,18,19).

In this study after incubation of the cells with conjugated nanoparticles, the blue stain induced by iron staining showed the accumulation of conjugated nanoparticles on the cell surface (Figure 4).
Discussion

Polymer-coated magnetic particles with particle sizes 5-500 nm have been employed in medicine or biotechnology for many years (16). In this study the 20 nm nanoparticles were coupled via their surface carboxyl group to the amino groups on the Herceptin antibody using the EDC method (10, 17).

After conjugation, the amount of immobilized antibody was approximately 20 μg/mg magnetite. However by increasing concentration of antibody during the process, the efficiency of the conjugation did not improve. In other studies the efficiency of conjugation has been reported as 5-20 μg Ab/mg particles (9,18). Conjugated nanoparticles bound specifically to the her2/neu antigen.

Iron staining, confirmed the presence of nanoparticles on the cell surface. In the present study we showed specific binding of Herceptin-nanomagnetic particle conjugates to her2/neu over expressing cells, suggesting a future application of Herceptin-magnetite for MR imaging of breast cancer.

Acknowledgment

This work was supported by a grant from the Nanotechnology Committee of Iran’s Ministry of Health and Medical Education.

References

3. Nagasaki Y, Kobayashi H, Katsuyama Y, Jomura T, Sakura T. Enhanced immunoresponse of
antibody mixed-PEG coimmobilized surface
construction of high performance immuno-
magnetic ELISA system. J Colloid Interface Sci

4. Baio G, Fabbri M, d. Totero D, Ferrini S, Cilli M,
Derchi LE, Neumaier CE. Magnetic resonance
imaging at 1.5T with immunospecific contrast
agent in vitro and in vivo in a xeno-transplant

5. Itoa A, Kugaa Y, Hondaa H, Kikkawab H,
nanoparticle-loaded anti-her2 immunoliposomes
for combination of antibody therapy with hyper-

6. Kawasaki ES, Player A. Nanotechnology, nano-
medicine, and the development of new, effective
101-109.

7. Lawson EL, Clifton JG, Huang F, Li X, Hixson
DC, Josic D. Use of magnetic beads with immo-
obilized monoclonal antibodies for isolation of
highly pure plasma membranes. Electrophoresis

8. Lee JH, Huh YM, Jun YW, Seo JW, Jang JT,
Song HT, et al. Artificially engineered magnetic
nanoparticles for ultra-sensitive molecular

9. Gruttnera C, Mullera K, Tellera J, Westphal F,
Foremanb A, Ivkovi b R. Synthesis and antibody
conjugation of magnetic nanoparticles with im-
proved specific power absorption rates for alter-
nating magnetic field cancer therapy. J Magn

10. Denardo SJ, Denardo G, Miers L, Natarajan A,
Foreman A, Gruettner C, et al. Development of
tumor targeting bio probes (111In-Chimeric L6
Monoclonal Antibody nanoparticles) for alter-
nating magnetic field cancer therapy. Clin Cancer

11. Bradford MM. A rapid and sensitive method for
the quantitation of microgram quantities of protein
utilizing the principle of protein-dye binding. Anal

12. Owen CS, Sykes NL. Magnetic labeling and cell

13. Funovicsa MA, Kapellerb B, Hoellerc C, Sud HS,
Kunstfelder R, Puiga S, et al. MR imaging of the
her2/neu and 9.2.27 tumor antigens using im-
munospecific contrast agents. Magn Reson Im-

14. Bancroft JD, Stevens A. Theory and Practice of
Histological Techniques, 4th ed. New York: Chur-
chill Livingstone Inc;1996.

15. Luna LG. Manual of Histological Staining
Hill; 1968.

16. Wagner K, Kautz A, Ro¨ der M, Schwalbe M,
Pachmann K, Clement JH, et al. Synthesis of
oligonucleotide-functionalized magnetic nano-
particles and study on their in vitro cell uptake.

17. Prestvikt WS, Berge A, Mork PC, Stenstad PM,
Ugelstad J. Preparation and application of mono-
sized particles in selective cell separation. In:
Scientific and clinical applications of magnetic

imaging of her2/neu protein using magnetic nano-
particles. Nanotechnology 2007;18(13):135103-
135111.

19. Zhang C, Jugold M, Woenne EC, Lammers T,
Morgenstern B, et al. Specific targeting of tumor
angiogenesis by RGD-conjugated ultra-small
superparamagnetic Iron oxide particles using a
clinical 1.5-T magnetic resonance scanner. Cancer